BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (“NPS”) (NASDAQ: NPSP) today announced the completion of its underwritten public offering of 12,650,000 shares of its common stock, which included 1,650,000 shares sold pursuant to the full exercise of an option granted to the underwriters to purchase additional shares. NPS expects that its net proceeds from the offering will be approximately $107 million after deducting underwriting discounts and commissions and other offering expenses.
